BioSpace News Archive

IONTAS Limited (IONTAS), , has been informed that International Biotechnology Center (IBC) Generium has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia (ALL).

Jasper Therapeutics, Inc., today announced that initial results from an ongoing Phase 1 dose-escalation study of its lead product candidate, JSP191 (formerly AMG191), will be presented today in an oral session at the American Society of Hematology (ASH) Annual Meeting & Exposition.

A team of medical experts from Israel’s Sheba Medical Center, Tel HaShomer is embarking on an emergency deployment to the Pacific island nation of Samoa following an urgent request from the World Health Organization (WHO) for humanitarian aid.

Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the expansion of its executive team with the appointment of Jean M. Franchi as Chief Financial Officer

Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two hepatitis B virus (HBV) poster presentations at HepDART 2019 being held December 8 - 12, 2019 in Kauai, Hawaii.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, today announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis.

BJ Bioscience Inc. (the ‘company’) today announced that the first patient was successfully dosed on December 4, 2019 in the first-in-human (FIH) trial of the company’s BJ-001 program at NEXT ONCOLOGY in San Antonio, Texas.

Menarini Ricerche is progressing with the clinical development of SEL24/MEN1703, and will be presenting the design of the ongoing First In Human clinical trial DIAMOND-01 (NCT03008187) at the 61st ASH Congress, with a poster entitled: “First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia.”

Canadian biotechnology company, Folium Labs Inc., gains an undisclosed investment led by YEDI Venture Fund to support the development of a new line of LIVLI products and respective IP.

Avitide, Inc., the industry leader in the discovery and development of custom affinity purification resins, announces that it has entered into an exclusive license agreement to support the development of one of Gemini Therapeutics’ therapeutic programs.